Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Confounding in association studies: month of birth and multiple sclerosis.
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
Leber's hereditary optic neuropathy associated with multiple sclerosis: Harding's syndrome.
The Many Facets of Cell Injury: Angiogenesis to Autophagy.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Artielle Immunotherapeutics Announces Positive Results of Phase ! Multiple Sclerosis Trial
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Rehabilitation interventions in multiple sclerosis: an overview.
A genome screen for multiple sclerosis in Italian families.
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
A comparative study of experimental mouse models of central nervous system demyelination.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.
Galectin-1 for neuroprotection?
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Clinical overview of the seizure risk of dalfampridine.

Pages